AP646A - Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. - Google Patents

Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. Download PDF

Info

Publication number
AP646A
AP646A APAP/P/1997/001092A AP9701092A AP646A AP 646 A AP646 A AP 646A AP 9701092 A AP9701092 A AP 9701092A AP 646 A AP646 A AP 646A
Authority
AP
ARIPO
Prior art keywords
fumagillol
preparation
fumagillin
drugs
ester
Prior art date
Application number
APAP/P/1997/001092A
Other languages
English (en)
Other versions
AP9701092A0 (en
Inventor
Jean-Michel Molina
Francis Deriyubm
Original Assignee
Sanofi Synthelabo
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Hopitaux Paris Assist Publique filed Critical Sanofi Synthelabo
Publication of AP9701092A0 publication Critical patent/AP9701092A0/xx
Application granted granted Critical
Publication of AP646A publication Critical patent/AP646A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1997/001092A 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. AP646A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
AP9701092A0 AP9701092A0 (en) 1997-10-31
AP646A true AP646A (en) 1998-04-27

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001092A AP646A (en) 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.

Country Status (25)

Country Link
US (1) US5900431A (enrdf_load_html_response)
EP (1) EP0817626B1 (enrdf_load_html_response)
JP (1) JP3260378B2 (enrdf_load_html_response)
KR (1) KR100286920B1 (enrdf_load_html_response)
CN (1) CN1072485C (enrdf_load_html_response)
AP (1) AP646A (enrdf_load_html_response)
AT (1) ATE172641T1 (enrdf_load_html_response)
AU (1) AU706161B2 (enrdf_load_html_response)
CA (1) CA2216623C (enrdf_load_html_response)
CZ (1) CZ286821B6 (enrdf_load_html_response)
DE (1) DE69600879T2 (enrdf_load_html_response)
DK (1) DK0817626T3 (enrdf_load_html_response)
EA (1) EA000150B1 (enrdf_load_html_response)
ES (1) ES2128846T3 (enrdf_load_html_response)
FR (1) FR06C0014I2 (enrdf_load_html_response)
HU (1) HU224028B1 (enrdf_load_html_response)
IS (1) IS2048B (enrdf_load_html_response)
NO (1) NO315968B1 (enrdf_load_html_response)
NZ (1) NZ304906A (enrdf_load_html_response)
OA (1) OA10515A (enrdf_load_html_response)
PL (1) PL183378B1 (enrdf_load_html_response)
SK (1) SK283883B6 (enrdf_load_html_response)
TR (1) TR199701048T1 (enrdf_load_html_response)
UA (1) UA41446C2 (enrdf_load_html_response)
WO (1) WO1996030010A2 (enrdf_load_html_response)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ304906A (en) * 1995-03-27 1999-06-29 Sanofi Sa Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
ES2286998T3 (es) * 1999-02-26 2007-12-16 Sanofi-Aventis Formulacion estable que contiene fumagillina.
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
CN101990441A (zh) * 2007-11-28 2011-03-23 默萨那治疗学股份有限公司 生物相容的生物可降解的烟曲霉素类似物轭合物
NZ590732A (en) * 2008-07-18 2012-09-28 Zafgen Inc Methods of treating an overweight or obese subject using fumagillin
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
JP5890312B2 (ja) 2009-10-09 2016-03-22 ザフゲン,インコーポレイテッド 肥満治療に用いられるスルホン化合物
CA2786603C (en) 2010-01-08 2018-02-20 James E. Vath Fumagillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
CN103249735B (zh) 2010-07-22 2016-04-06 扎夫根股份有限公司 三环化合物及其制备和使用方法
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン,インコーポレイテッド 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療
CA2825408A1 (en) 2011-01-26 2012-08-02 Zafgen, Inc. Tetrazole compounds and methods of making and using same
WO2012122264A1 (en) 2011-03-08 2012-09-13 Zafgen Corporation Oxaspiro [2.5] octane derivatives and analogs
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
EP2705035B1 (en) 2011-05-06 2016-12-14 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
EP2705036B1 (en) 2011-05-06 2015-08-12 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
AU2013209723B2 (en) 2012-01-18 2016-11-24 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン,インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
KR20150016303A (ko) 2012-05-07 2015-02-11 자프겐 인크. 6-o-(4-디메틸아미노에톡시) 신나모일 푸마지롤의 옥살레이트 염의 다형체 염 및 이의 제조 및 사용 방법
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
JP6177888B2 (ja) 2012-05-09 2017-08-09 ザフゲン,インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
MX2015005734A (es) 2012-11-05 2016-02-10 Zafgen Inc Metodos de tratamiento de enfermedades hepaticas.
JP2015536981A (ja) 2012-11-05 2015-12-24 ザフゲン,インコーポレイテッド 三環式化合物ならびにその製造および使用方法
US9597309B2 (en) 2013-03-14 2017-03-21 Zafgen, Inc. Methods of treating renal disease and other disorders
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
CA2082804A1 (en) * 1990-07-27 1992-01-28 Theodore Maione Methods and compositions for treatment of angiogenic diseases
NZ304906A (en) * 1995-03-27 1999-06-29 Sanofi Sa Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
WO1998005293A2 (en) * 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Also Published As

Publication number Publication date
CZ304997A3 (en) 1997-12-17
AU5278696A (en) 1996-10-16
OA10515A (fr) 2002-04-24
AU706161B2 (en) 1999-06-10
HUP9801220A2 (hu) 1999-09-28
JP3260378B2 (ja) 2002-02-25
ES2128846T3 (es) 1999-05-16
HU224028B1 (hu) 2005-05-30
NO974466D0 (no) 1997-09-26
PL322470A1 (en) 1998-02-02
DK0817626T3 (da) 1999-07-12
US5900431A (en) 1999-05-04
DE69600879D1 (de) 1998-12-03
IS2048B (is) 2005-09-15
CA2216623C (en) 2005-05-31
FR06C0014I2 (enrdf_load_html_response) 2006-12-29
HUP9801220A3 (en) 2001-10-29
EP0817626B1 (fr) 1998-10-28
TR199701048T1 (xx) 1998-01-21
EA000150B1 (ru) 1998-10-29
CZ286821B6 (en) 2000-07-12
SK283883B6 (sk) 2004-04-06
WO1996030010A3 (fr) 1996-11-28
DE69600879T2 (de) 1999-06-02
EP0817626A2 (fr) 1998-01-14
MX9707150A (es) 1998-07-31
NZ304906A (en) 1999-06-29
AP9701092A0 (en) 1997-10-31
FR06C0014I1 (enrdf_load_html_response) 2006-11-17
EA199700267A1 (ru) 1998-04-30
JPH11506421A (ja) 1999-06-08
IS4557A (is) 1997-09-11
NO974466L (no) 1997-09-26
KR19980703271A (ko) 1998-10-15
ATE172641T1 (de) 1998-11-15
KR100286920B1 (ko) 2001-04-16
CN1179715A (zh) 1998-04-22
CA2216623A1 (en) 1996-10-03
PL183378B1 (pl) 2002-06-28
NO315968B1 (no) 2003-11-24
WO1996030010A2 (fr) 1996-10-03
CN1072485C (zh) 2001-10-10
UA41446C2 (uk) 2001-09-17
SK130797A3 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
AP646A (en) Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
US4101647A (en) Oral dosage form for X-ray contrast media containing a pharmaceutically acceptable base and method of use thereof
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
EP0190851B1 (en) Improved antiinflammatory composition
US4895851A (en) Use of oxoquinazoline derivatives in the treatment of hyperuricaemia
MXPA97007150A (en) Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections
AU748883B2 (en) Method of treating pulmonary hypertension
WO1992007564A2 (en) Method of treating demyelinating disease
AU5687900A (en) A method for the treatment or prevention of coronary graft vasospasm
US20070093519A1 (en) Anti-emetic uses of cannabinoid analogs
Kutscher et al. Amphotericin B in the treatment of oral monilial infections
US7485642B2 (en) Method for treating septic shock
EP0402477B1 (en) Use of isocarbacyclins for preventing or treating organ diseases
Stratigos et al. Treatment of gonorrhoea with spectinomycin hydrochloride
JPH0132804B2 (enrdf_load_html_response)
JPH04266822A (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
EP0118968A1 (en) Use of avilamycin to control swine dysentery
EA007488B1 (ru) Фармацевтические композиции с контролируемым высвобождением, содержащие альгинат натрия и альгинат натрия-кальция
FR2566664A1 (fr) Composition utile au traitement de la diarrhee contenant du dextromethorphan
US20040044016A1 (en) Antiviral agents
JPS58210010A (ja) 抗腫瘍剤
JPH02174721A (ja) 脂質低下剤
JPH02275822A (ja) 語音聴力改善剤
JPH0899883A (ja) 膵炎治療剤